DGAP-News

ImevaX secures EUR 7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections - Seite 3

BioMedPartners currently invest out of their BioMedInvest II LP fund, which
has a size of CHF 106 million, and was closed in 2009. For more information
please visit: www.biomedvc.com.

About EMBL Ventures
EMBL Ventures is an independent venture capital investor that manages two
funds with a total of EUR 68 million capital on behalf of major European
institutional and private investors. EMBL Ventures' close relationship with
the European Molecular Biology Laboratory (EMBL) and its technology
transfer organization EMBL Enterprise Management Technology Transfer GmbH
(EMBLEM) allows it to finance disruptive technologies in an entrepreneurial
start-up environment, aiming ultimately for a transaction with a partner
that is seeking to acquire external product innovation. EMBL Ventures is
exclusively focused on life-science investments. Further information at
www.embl-ventures.com.

About Santo Venture Capital
Santo Venture Capital is the venture arm of ATHOS Service GmbH, the Family
Office of the Strüngmann family.


For further information, please contact:


Volker Wedershoven Katja Arnold (CIRO)
Chief Executive Officer Executive Director
ImevaX GmbH MC Services AG
Tel: [phone] Tel: [phone]
Email: [e-mail] Email: [e-mail]



---------------------------------------------------------------------

28.10.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


293534 28.10.2014